Whether the PD-1+ subpopulation among circulating CD3+ T cells or CD56+ natural killer cells represents an appropriate biomarker on the basis of which NSCLC patients are selected for PD-1 blockade therapy remains to be resolved. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.